Gain-of-function mutations in the catalytic domain of <i>DOT1L</i> promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway
Lihui Wang(Shenyang Pharmaceutical University)
Cited by 22
Related Papers
Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity
|Cell Death and Disease|2017|134
An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer
|Molecular Cancer|2022|62
<p>LINC00565 promotes proliferation and inhibits apoptosis of gastric cancer by targeting miR-665/AKT3 axis</p>
|OncoTargets and Therapy|2019|25
Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK-dependent p21 signaling pathway
|Scientific Reports|2016|19
DNMT3A loss drives a HIF-1-dependent synthetic lethality to HDAC6 inhibition in non-small cell lung cancer
|Acta Pharmaceutica Sinica B|2024|11